GAITHERSBURG, Maryland (Reuters) - Pfizer Inc.'s pain reliever Celebrex should be approved for treating rheumatoid arthritis in children despite uncertainty about the risks of long-term use, U.S.
CHICAGO (Reuters) - Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results